$12.02 Million in Sales Expected for BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) This Quarter

Analysts expect BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) to report $12.02 million in sales for the current quarter, according to Zacks. Four analysts have issued estimates for BioCryst Pharmaceuticals’ earnings, with the lowest sales estimate coming in at $1.90 million and the highest estimate coming in at $29.50 million. BioCryst Pharmaceuticals posted sales of $2.73 million in the same quarter last year, which would indicate a positive year-over-year growth rate of 340.3%. The business is scheduled to announce its next earnings report on Monday, March 2nd.

On average, analysts expect that BioCryst Pharmaceuticals will report full-year sales of $21.13 million for the current year, with estimates ranging from $11.00 million to $38.61 million. For the next fiscal year, analysts anticipate that the company will post sales of $39.51 million, with estimates ranging from $10.00 million to $87.47 million. Zacks Investment Research’s sales averages are a mean average based on a survey of research analysts that cover BioCryst Pharmaceuticals.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last issued its earnings results on Wednesday, November 6th. The biotechnology company reported ($0.34) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.31) by ($0.03). BioCryst Pharmaceuticals had a negative net margin of 1,129.38% and a negative return on equity of 2,511.40%. The company had revenue of $1.78 million for the quarter, compared to analysts’ expectations of $4.54 million.

A number of analysts recently weighed in on BCRX shares. Bank of America raised shares of BioCryst Pharmaceuticals from a “neutral” rating to a “buy” rating and lowered their price objective for the stock from $5.00 to $4.00 in a research note on Friday, November 15th. HC Wainwright reaffirmed a “buy” rating and issued a $13.00 price objective on shares of BioCryst Pharmaceuticals in a research note on Thursday, October 31st. BidaskClub lowered shares of BioCryst Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Thursday. Needham & Company LLC reaffirmed a “hold” rating on shares of BioCryst Pharmaceuticals in a research note on Wednesday, November 6th. Finally, ValuEngine raised shares of BioCryst Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Tuesday, December 3rd. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and seven have given a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus target price of $8.19.

In other news, insider Megan Sniecinski purchased 45,000 shares of the firm’s stock in a transaction on Monday, November 18th. The stock was acquired at an average cost of $1.45 per share, with a total value of $65,250.00. Following the completion of the transaction, the insider now owns 45,000 shares in the company, valued at approximately $65,250. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CEO Jon P. Stonehouse purchased 50,000 shares of the firm’s stock in a transaction on Monday, November 18th. The shares were purchased at an average cost of $1.45 per share, with a total value of $72,500.00. Following the completion of the transaction, the chief executive officer now owns 778,086 shares of the company’s stock, valued at approximately $1,128,224.70. The disclosure for this purchase can be found here. Over the last three months, insiders have acquired 120,000 shares of company stock valued at $174,000. Insiders own 5.20% of the company’s stock.

Several hedge funds have recently added to or reduced their stakes in BCRX. FMR LLC lifted its position in shares of BioCryst Pharmaceuticals by 15.9% during the first quarter. FMR LLC now owns 3,467,998 shares of the biotechnology company’s stock valued at $28,229,000 after buying an additional 475,989 shares during the last quarter. Wells Fargo & Company MN lifted its position in shares of BioCryst Pharmaceuticals by 114.8% during the second quarter. Wells Fargo & Company MN now owns 183,419 shares of the biotechnology company’s stock valued at $695,000 after buying an additional 98,038 shares during the last quarter. Bank of Montreal Can lifted its position in shares of BioCryst Pharmaceuticals by 921.9% during the second quarter. Bank of Montreal Can now owns 10,219 shares of the biotechnology company’s stock valued at $39,000 after buying an additional 9,219 shares during the last quarter. Quantamental Technologies LLC purchased a new stake in shares of BioCryst Pharmaceuticals during the second quarter valued at about $43,000. Finally, Virtus ETF Advisers LLC lifted its position in shares of BioCryst Pharmaceuticals by 151.6% during the second quarter. Virtus ETF Advisers LLC now owns 78,684 shares of the biotechnology company’s stock valued at $298,000 after buying an additional 47,407 shares during the last quarter. 66.55% of the stock is owned by institutional investors and hedge funds.

NASDAQ:BCRX traded down $0.05 during mid-day trading on Friday, reaching $2.78. The company’s stock had a trading volume of 4,869,218 shares, compared to its average volume of 2,645,843. BioCryst Pharmaceuticals has a 1 year low of $1.38 and a 1 year high of $9.95. The stock has a fifty day moving average of $3.04 and a 200-day moving average of $2.86. The firm has a market capitalization of $419.88 million, a PE ratio of -2.84 and a beta of 2.10.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, discovers oral and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor, for the treatment of acute uncomplicated influenza under the RAPIVAB, ALPIVAB, RAPIACTA, and PERAMIFLU names; and Mundesine, an oral purine nucleoside phosphorylase inhibitor for peripheral T-cell lymphoma.

Further Reading: Are sell-side analysts objective?

Get a free copy of the Zacks research report on BioCryst Pharmaceuticals (BCRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for BioCryst Pharmaceuticals (NASDAQ:BCRX)

Receive News & Ratings for BioCryst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.